Vestcor Inc Acquires 2,651 Shares of McKesson Corporation $MCK

Key Points

• Vestcor Inc increased its stake in McKesson by 19.8%, adding 2,651 shares to hold 16,050 shares valued at $12,399,000, and institutional investors now own about 85.07% of the stock.
• Analysts give McKesson a consensus rating of “Moderate Buy” with an average target of $960.93, and firms like JPMorgan have raised targets (JPMorgan to $1,107), with 13 Buys vs. 4 Holds.
• McKesson beat quarterly estimates with EPS $9.34 vs. $9.19 and revenue of $106.16B (up 11.4% YoY), and issued FY2026 EPS guidance of 38.80–39.20.

Vestcor Inc increased its stake in shares of McKesson Corporation (NYSE:MCK - Free Report) by 19.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,050 shares of the company's stock after acquiring an additional 2,651 shares during the quarter. Vestcor Inc's holdings in McKesson were worth $12,399,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of MCK. Russell Investments Group Ltd. increased its holdings in shares of McKesson by 0.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 321,175 shares of the company's stock worth $247,678,000 after purchasing an additional 1,640 shares during the period. Schroder Investment Management Group lifted its stake in shares of McKesson by 4.2% in the third quarter. Schroder Investment Management Group now owns 153,087 shares of the company's stock valued at $118,266,000 after buying an additional 6,213 shares during the period. ProVise Management Group LLC grew its position in McKesson by 4.2% during the third quarter. ProVise Management Group LLC now owns 14,558 shares of the company's stock worth $11,247,000 after buying an additional 585 shares in the last quarter. Pinnacle Associates Ltd. grew its position in McKesson by 5.3% during the third quarter. Pinnacle Associates Ltd. now owns 2,620 shares of the company's stock worth $2,024,000 after buying an additional 132 shares in the last quarter. Finally, B. Metzler seel. Sohn & Co. AG increased its stake in McKesson by 13.4% during the third quarter. B. Metzler seel. Sohn & Co. AG now owns 6,860 shares of the company's stock valued at $5,300,000 after acquiring an additional 808 shares during the period. 85.07% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on MCK. Raymond James Financial set a $970.00 price target on McKesson in a report on Thursday. Robert W. Baird set a $968.00 price objective on McKesson in a research report on Wednesday, January 14th. Deutsche Bank Aktiengesellschaft restated a "buy" rating on shares of McKesson in a research note on Wednesday, December 10th. JPMorgan Chase & Co. raised their target price on McKesson from $983.00 to $1,107.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 10th. Finally, Weiss Ratings downgraded shares of McKesson from a "buy (a-)" rating to a "buy (b+)" rating in a research note on Thursday, February 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, McKesson has a consensus rating of "Moderate Buy" and an average target price of $960.93.

Insider Buying and Selling

In other McKesson news, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the business's stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Michele Lau sold 2,725 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $990.00, for a total transaction of $2,697,750.00. Following the sale, the executive vice president directly owned 3,247 shares in the company, valued at $3,214,530. This represents a 45.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,868 shares of company stock worth $3,743,820 in the last three months. Company insiders own 0.08% of the company's stock.

McKesson Trading Down 1.4%

MCK stock opened at $918.37 on Monday. McKesson Corporation has a 1-year low of $633.53 and a 1-year high of $999.00. The business's 50 day moving average is $882.53 and its 200-day moving average is $817.53. The firm has a market cap of $112.49 billion, a P/E ratio of 26.41, a P/E/G ratio of 1.48 and a beta of 0.38.

McKesson (NYSE:MCK - Get Free Report) last posted its earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, topping the consensus estimate of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter last year, the company earned $8.03 EPS. McKesson's revenue was up 11.4% on a year-over-year basis. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Sell-side analysts forecast that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson's dividend payout ratio (DPR) is presently 9.43%.

McKesson Profile

McKesson Corporation NYSE: MCK is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company's core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.